Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT2109 in Active Psoriatic Arthritis
NCT07869134Phase 2Not yet recruiting
- Sponsor
- Forward Therapeutics
- Start
- Dec 2026
- Primary completion
- Oct 2027
01
Overview
A Phase 2 trial of FT2109 in psoriatic arthritis (PsA), sponsored by Forward Therapeutics. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
FT2109
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07869134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869134.